Candriam S.C.A. Boosts Stake in Vera Therapeutics, Inc. $VERA

Candriam S.C.A. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 43.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 427,189 shares of the company’s stock after acquiring an additional 130,248 shares during the period. Candriam S.C.A.’s holdings in Vera Therapeutics were worth $12,414,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Virtus Investment Advisers LLC boosted its holdings in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after purchasing an additional 539 shares during the last quarter. Invesco Ltd. increased its holdings in Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after purchasing an additional 550 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Vera Therapeutics by 13.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after purchasing an additional 615 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Vera Therapeutics by 2.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock valued at $744,000 after buying an additional 816 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after buying an additional 825 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 0.5%

Shares of NASDAQ:VERA opened at $44.05 on Wednesday. The company’s fifty day moving average is $47.40 and its two-hundred day moving average is $33.70. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $56.05. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -11.04 and a beta of 1.16.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VERA shares. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. The Goldman Sachs Group boosted their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Evercore upped their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a research note on Friday, November 28th. Finally, Bank of America boosted their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a report on Friday, December 19th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.18.

Insiders Place Their Bets

In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the purchase, the director directly owned 5,882 shares in the company, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 16.30% of the stock is currently owned by company insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.